Angelo Tozzi

Angelo Tozzi

Auto-generated profile, based on publicly available information

Angelo Tozzi

Humanitas Clinical and Research Center

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MSMarta Scorsetti
Marta Scorsetti
SAStefano Arcangeli
Stefano Arcangeli
ATAngelo Tozzi
Angelo Tozzi
TCTiziana Comito
Tiziana Comito
Filippo AlongiFilippo Alongi
Filippo Alongi
LCLuca Cozzi
Luca Cozzi

23 September 2014 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MSMarta Scorsetti
Marta Scorsetti
TCTiziana Comito
Tiziana Comito
ATAngelo Tozzi
Angelo Tozzi
Pierina NavarriaPierina Navarria
Pierina Navarria
AFAntonella Fogliata
Antonella Fogliata
LCLuca Cozzi
Luca Cozzi

3 February 2015 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MSMarta Scorsetti
Marta Scorsetti
TCTiziana Comito
Tiziana Comito
LCLuca Cozzi
Luca Cozzi
ECElena Clerici
Elena Clerici
ATAngelo Tozzi
Angelo Tozzi
Guido TorzilliGuido Torzilli
Guido Torzilli

1 June 2013 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
Pierina NavarriaPierina Navarria
Pierina Navarria
AAAnna Maria Ascolese
Anna Maria Ascolese
PMPietro Mancosu
Pietro Mancosu
Filippo AlongiFilippo Alongi
Filippo Alongi
ECElena Clerici
Elena Clerici
MSMarta Scorsetti
Marta Scorsetti

12 September 2011 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MSMarta Scorsetti
Marta Scorsetti
Filippo AlongiFilippo Alongi
Filippo Alongi
SCSimona Castiglioni
Simona Castiglioni
ACAlessandro Clivio
Alessandro Clivio
AFAntonella Fogliata
Antonella Fogliata
LCLuca Cozzi
Luca Cozzi
Purpose: To test feasibility and safety of clinical usage of Flattening Filter Free (FFF) beams for delivering ablative stereotactic body radiation therapy (SBRT) doses to various tumor sites, by means of Varian TrueBeam™ (Varian Medical Systems). Methods and Materials: Seventy patients were treated with SBRT and FFF: 51 lesions were in the thorax (48 patients),10 in the liver, 9 in isolated abdominal lymph node, adrenal gland or pancreas. Doses ranged from 32 to 75 Gy, depending on the anatomical site and the volume of the lesion to irradiate. Lung lesions were treated with cumulative doses of 32 or 48 Gy, delivered in 4 consecutive fractions. The liver patients were treated in 3 fractions with total dose of 75 Gy. The isolated lymph nodes were irradiated in 6 fractions with doses of 45 Gy. The inclusion criteria were the presence of isolated node, or few lymph nodes in the same lymph node region, in absence of other active sites of cancer disease before the SBRT treatment. Results: All 70 patients completed the treatment. The minimum follow-up was 3 months. Six cases of acute toxicities were recorded (2 Grade2 and 2 Grade3 in lung and 2 Grade2 in abdomen). No patient experienced acute toxicity greater than Grade3. No other types or grades of toxicities were observed at clinical evaluation visits. Conclusions: This study showed that, with respect to acute toxicity, SBRT with FFF beams showed to be a feasible technique in 70 consecutive patients with various primary and metastatic lesions in the body.

31 October 2015 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
AFAntonella Fogliata
Antonella Fogliata
GNGiorgia Nicolini
Giorgia Nicolini
ACAlessandro Clivio
Alessandro Clivio
EVEugenio Vanetti
Eugenio Vanetti
SLSarbani Laksar
Sarbani Laksar
LCLuca Cozzi
Luca Cozzi
To evaluate the performance of a broad scope model-based optimisation process for volumetric modulated arc therapy applied to esophageal cancer. A set of 70 previously treated patients in two different institutions, were selected to train a model for the prediction of dose-volume constraints. The model was built with a broad-scope purpose, aiming to be effective for different dose prescriptions and tumour localisations. It was validated on three groups of patients from the same institution and from another clinic not providing patients for the training phase. Comparison of the automated plans was done against reference cases given by the clinically accepted plans. Quantitative improvements (statistically significant for the majority of the analysed dose-volume parameters) were observed between the benchmark and the test plans. Of 624 dose-volume objectives assessed for plan evaluation, in 21 cases (3.3 %) the reference plans failed to respect the constraints while the model-based plans succeeded. Only in 3 cases (<0.5 %) the reference plans passed the criteria while the model-based failed. In 5.3 % of the cases both groups of plans failed and in the remaining cases both passed the tests. Plans were optimised using a broad scope knowledge-based model to determine the dose-volume constraints. The results showed dosimetric improvements when compared to the benchmark data. Particularly the plans optimised for patients from the third centre, not participating to the training, resulted in superior quality. The data suggests that the new engine is reliable and could encourage its application to clinical practice.